Human Pathology
Volume 40, Issue 12 , Pages 1671-1678 , December 2009

Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis

  • Adeboye O. Osunkoya, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    • Department of Urology, Emory University School of Medicine, Atlanta, GA 30322, USA
    • ,
  • Qiqin Yin-Goen, MS

      Affiliations

    • Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    • ,
  • John H. Phan, PhD

      Affiliations

    • Wallace H Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, GA 30322, USA
    • ,
  • Richard A. Moffitt, BS

      Affiliations

    • Wallace H Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, GA 30322, USA
    • ,
  • Todd H. Stokes, BS

      Affiliations

    • Wallace H Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, GA 30322, USA
    • ,
  • May D. Wang, PhD

      Affiliations

    • Wallace H Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, GA 30322, USA
    • ,
  • Andrew N. Young, MD, PhD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    • Corresponding Author InformationCorresponding author. Grady Health System, Emory University Department of Pathology & Laboratory Medicine, Grady Memorial Hospital D-119, Atlanta, GA 30303, USA.

Received 23 February 2009 ,Revised 4 May 2009 ,Accepted 7 May 2009.

References 

  1. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281–291
  2. Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2004;11:71–77
  3. Schuetz AN, Yin-Goen Q, Amin MB, et al. Molecular classification of renal tumors by gene expression profiling. J Mol Diagn. 2005;7:206–218
  4. Takahashi M, Yang XJ, Sugimura J, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene. 2003;22:6810–6818
  5. Yang XJ, Sugimura J, Schafernak KT, et al. Classification of renal neoplasms based on molecular signatures. J Urol. 2006;175:2302–2306
  6. Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001;158:1639–1651
  7. Osunkoya AO, Cohen C, Lawson D, et al. Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma. Hum Pathol. 2009;40:206–210
  8. Pan CC, Chen PC, Chiang H. Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol. 2004;121:878–883
  9. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28:69–76
  10. Young AN, de Oliveira Salles PG, Lim SD, et al. Beta defensin-1, parvalbumin, and vimentin: a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays. Am J Surg Pathol. 2003;27:199–205
  11. Stokes TH, Phan J, Quo CF, et al. Bio-nano-informatics: an integrated information management system for personalized oncology. Conf Proc IEEE Eng Med Biol Soc. 2006;1:3325–3328
  12. Jones J, Otu H, Spentzos D, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 2005;11:5730–5739
  13. Stokes TH, Torrance JT, Li H, et al. ArrayWiki: an enabling technology for sharing public microarray data repositories and meta-analyses. BMC Bioinformatics. 2008;9(Suppl 6):S18
  14. Stokes TH, Moffitt RA, Phan JH, et al. chip artifact CORRECTion (caCORRECT): a bioinformatics system for quality assurance of genomics and proteomics array data. Ann Biomed Eng. 2007;35:1068–1080
  15. Steinhoff C, Vingron M. Normalization and quantification of differential expression in gene expression microarrays. Brief Bioinform. 2006;7:166–177
  16. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249–264
  17. Phan JH, Young AN, Wang MD. Selecting clinically-driven biomarkers for cancer nanotechnology. Conf Proc IEEE Eng Med Biol Soc. 2006;1:3317–3320
  18. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863–14868
  19. Huynh KN, Phan JH, Vo TM, et al. Improved bolstering error estimation for gene ranking. Conf Proc IEEE Eng Med Biol Soc. 2007;2007:4633–4636
  20. Chen YT, Tu JJ, Kao J, et al. Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res. 2005;11:6558–6566
  21. Zeeberg BR, Feng W, Wang G, et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol. 2003;4:R28
  22. Specht K, Richter T, Muller U, et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol. 2001;158:419–429
  23. Chuang ST, Chu P, Sugimura J, et al. Overexpression of glutathione s-transferase alpha in clear cell renal cell carcinoma. Am J Clin Pathol. 2005;123:421–429
  24. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol. 2003;162:925–932
  25. Yao M, Tabuchi H, Nagashima Y, et al. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol. 2005;205:377–387
  26. Salzberg SL. Genome re-annotation: a wiki solution?. Genome Biol. 2007;8:102
  27. Giles J. Key biology databases go wiki. Nature. 2007;445:691
  28. Dorai T, Sawczuk IS, Pastorek J, et al. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer. 2005;41:2935–2947
  29. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802–811
  30. Patard JJ, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008;123:395–400
  31. Shuch B, Li Z, Belldegrun AS. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies. BJU Int. 2008;101(Suppl 4):25–30
  32. Stassar MJ, Devitt G, Brosius M, et al. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer. 2001;85:1372–1382
  33. Nishie A, Masuda K, Otsubo M, et al. High expression of the Cap43 gene in infiltrating macrophages of human renal cell carcinomas. Clin Cancer Res. 2001;7:2145–2151
  34. Pejovic M, Djordjevic V, Ignjatovic I, et al. Serum levels of some acute phase proteins in kidney and urinary tract urothelial cancers. Int Urol Nephrol. 1997;29:427–432
  35. Senra Varela A, Lopez Saez JJ, Quintela Senra D. Serum ceruloplasmin as a diagnostic marker of cancer. Cancer Lett. 1997;121:139–145
  36. Nayak SB, Bhat VR, Upadhyay D, et al. Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian J Physiol Pharmacol. 2003;47:108–110
  37. Nayak SB, Bhat VR, Mayya SS. Serum copper, ceruloplasmin and thiobarbituric acid reactive substance status in patients with ovarian cancer. Indian J Physiol Pharmacol. 2004;48:486–488
  38. Boz A, Evliyaoglu O, Yildirim M, et al. The value of serum zinc, copper, ceruloplasmin levels in patients with gastrointestinal tract cancers. Turk J Gastroenterol. 2005;16:81–84
  39. Zowczak M, Iskra M, Paszkowski J, et al. Oxidase activity of ceruloplasmin and concentrations of copper and zinc in serum of cancer patients. J Trace Elem Med Biol. 2001;15:193–196
  40. Goutebroze L, Brault E, Muchardt C, et al. Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins. Mol Cell Biol. 2000;20:1699–1712
  41. Scoles DR. The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta. 2008;1785:32–54
  42. Brembeck FH, Opitz OG, Libermann TA, et al. Dual function of the epithelial specific ETX transcription factor, ELF3, in modulating differentiation. Oncogene. 2000;19:1941–1949
  43. Tymms MJ, Ng AY, Thomas RS, et al. A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer. Oncogene. 1997;15:2449–2462
  44. He J, Pan Y, Hu J, et al. Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther. 2007;6:76–82
  45. Tschoep K, Kohlmann A, Schlemmer M, et al. Gene expression profiling in sarcomas. Crit Rev Oncol Hematol. 2007;63:111–124
  46. Manavathi B, Rayala SK, Kumar R. Phosphorylation-dependent regulation of stability and transforming potential of ETS transcriptional factor ESE-1 by p21-activated kinase 1. J Biol Chem. 2007;282:19820–19830
  47. Prescott JD, Koto KS, Singh M, et al. The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism. Mol Cell Biol. 2004;24:5548–5564
  48. Chang J, Lee C, Hahm KB, et al. Over-expression of ERT(ESX/ESE-1/ELF3), an ETS-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells. Oncogene. 2000;19:151–154
  49. Neve RM, Ylstra B, Chang CH, et al. ErbB2 activation of ESX gene expression. Oncogene. 2002;21:3934–3938
  50. Scott GK, Chang CH, Erny KM, et al. Ets regulation of the erbB2 promoter. Oncogene. 2000;19:6490–6502
  51. Uddin M, Opazo JC, Wildman DE, et al. Molecular evolution of the cytochrome c oxidase subunit 5A gene in primates. BMC Evol Biol. 2008;8:8
  52. Nishigaki R, Osaki M, Hiratsuka M, et al. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics. 2005;5:3205–3213
  53. Tickoo SK, Lee MW, Eble JN, et al. Ultrastructural observations on mitochondria and microvesicles in renal oncocytoma, chromophobe renal cell carcinoma, and eosinophilic variant of conventional (clear cell) renal cell carcinoma. Am J Surg Pathol. 2000;24:1247–1256
  54. Simonnet H, Alazard N, Pfeiffer K, et al. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis. 2002;23:759–768
  55. Chang TY, Chang CC, Ohgami N, et al. Cholesterol sensing, trafficking, and esterification. Annu Rev Cell Dev Biol. 2006;22:129–157
  56. Yang JB, Duan ZJ, Yao W, et al. Synergistic transcriptional activation of human Acyl-coenzyme A: cholesterol acyltransterase-1 gene by interferon-gamma and all-trans-retinoic acid THP-1 cells. J Biol Chem. 2001;276:20989–20998
  57. Locke JA, Wasan KM, Nelson CC, et al. Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:cholesterol acyltransferase (ACAT). Prostate. 2008;68:20–33
  58. Oliva E, Young RH, Amin MB, et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol. 2002;26:403–412
  59. Qian X, Peng XH, Ansari DO, et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol. 2008;26:83–90
  60. Xing Y, Chaudry Q, Shen C, et al. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc. 2007;2:1152–1165
  61. Kummerlin I, ten Kate F, Smedts F, et al. Core biopsies of renal tumors: a study on diagnostic accuracy, interobserver, and intraobserver variability. Eur Urol. 2008;53:1219–1225
  62. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20:2376–2381

☆ The authors declare no conflicts of interest related to this work.

☆☆ This work was supported by a grant from the National Cancer Institute Centers for Cancer Nanotechnology Excellence Program (U54CA119338).

PII: S0046-8177(09)00175-0

doi: 10.1016/j.humpath.2009.05.006

Human Pathology
Volume 40, Issue 12 , Pages 1671-1678 , December 2009

Article Tools

* Image Usage & Resolution